Nippon Kayaku acquires Asian rights to Spectrum's bladder cancer drug
This article was originally published in Scrip
The Japanese oncology specialist Nippon Kayaku has acquired Asian rights to Spectrum Pharmaceuticals' bladder cancer product apaziquone, for $15 million upfront and up to $136 million in regulatory and commercial milestones.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.